Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study.

ABSTRACT:

Background

Adjuvant treatments with PD-1 and BRAF+MEK inhibitors statistically significantly prolong recurrence-free survival in stage III cutaneous melanoma. Yet, the effect on overall survival is still unclear. Based on recurrence-free survival outcomes, these treatments have been approved and widely implemented. The treatments have considerable side effects and costs, and overall survival effect remains a highly anticipated outcome.

Methods

Clinical and histopathological parameters were obtained from the Swedish Melanoma Registry for patients diagnosed with stage III melanoma between 2016 and 2020. The patients were divided depending on if they were diagnosed before or from July 2018, based on the timepoint when adjuvant treatment was introduced in Sweden. Patients were f

SUBMITTER: Helgadottir H 

PROVIDER: S-EPMC10483326 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature